{"product_id":"aptar-swot-analysis","title":"Aptar SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAptar’s blend of durable packaging tech, global scale, and R\u0026amp;D strength positions it well in growing markets like beauty and pharma, but exposure to raw‑material costs and cyclic demand creates near‑term risks; our full SWOT unpacks competitive moats, margin drivers, and strategic options with data-driven recommendations. Purchase the complete SWOT to receive a ready-to-present Word report and editable Excel matrix for planning and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Pharmaceutical Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAptar holds a leadership position in proprietary drug-delivery systems, notably nasal and pulmonary devices, supplying \u0026gt;60% of global metered-dose spray systems and serving top pharma clients under multi-year contracts; high switching costs and quality validation cycles drive \u0026gt;25% gross margins in this segment and predict steady revenue through 2025, contributing roughly $650–700M to 2024 sales and recurring cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAptar Pharma and Consumer Care holds ~3,500 global patents and pending filings in dispensing and sealing tech, creating a durable moat that limits low-cost replication; this helped sustain gross margin near 34% in FY2024 and supported R\u0026amp;D spend of $156M (about 4.5% of revenue) to keep its innovation pipeline aligned with shifting consumer needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Blue-Chip Client Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAptar serves an impressive roster of global blue-chip clients in food, beverage, beauty and healthcare, with top-20 customers accounting for about 45% of 2024 revenue, anchoring demand. These partnerships often include co-development of dispensing and closure systems, embedding Aptar in clients’ supply chains and raising switching costs. The result: lower churn, more predictable cash flow—Aptar reported $1.79B revenue in FY2024, aiding multi-year planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAptar operates manufacturing plants across North America, Europe, Asia and South America, letting it supply global brands locally and cut cross-border logistics. This decentralized footprint reduced freight exposure and supported 2024 net sales of $2.2 billion by shortening lead times and lowering inventory in transit. By end-2025, the scale remains a clear edge versus smaller regional competitors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal plants: 20+ sites (2025)\u003c\/li\u003e\n\u003cli\u003e2024 net sales: $2.2B\u003c\/li\u003e\n\u003cli\u003eShorter lead times: ~15% faster vs centralized model\u003c\/li\u003e\n\u003cli\u003eLowered logistics spend: estimated 8% reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAptar maintains high regulatory compliance, meeting FDA regulations and holding ISO certifications across its pharma and food-grade sites—critical for servicing healthcare and consumer-packaged goods clients. In 2024 Aptar reported ~38% of sales from healthcare-related products, underscoring the business impact of compliance. This trust barrier raises entry costs for new competitors and supports premium pricing with risk-averse partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-regulated facilities\u003c\/li\u003e\n\u003cli\u003eISO-certified sites\u003c\/li\u003e\n\u003cli\u003e~38% 2024 revenue from healthcare\u003c\/li\u003e\n\u003cli\u003eHigh trust = pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAptar: Dominant MDI Leader—3,500 Patents, $2.2B Sales, Strong Pharma Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAptar leads in drug-delivery devices (\u0026gt;60% market share MDIs), 3,500 patents, $2.2B net sales (2024) with ~$650–700M from pharma devices, 34% gross margin (Pharma+Consumer), $156M R\u0026amp;D (2024), 20+ global plants (2025), ~38% revenue healthcare—driving high switching costs, stable cash flow, and pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$2.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma device sales\u003c\/td\u003e\n\u003ctd\u003e$650–700M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~34% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$156M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~3,500 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal plants\u003c\/td\u003e\n\u003ctd\u003e20+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare revenue\u003c\/td\u003e\n\u003ctd\u003e~38% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Aptar, outlining its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a focused SWOT summary of Aptar for rapid strategic alignment and executive briefings, making it easy to communicate positioning and priorities across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAptar is highly exposed to plastic resin and other petroleum-based raw material swings; resin accounted for roughly 20–25% of COGS in 2023, and resin spot prices jumped ~45% in 2021–22, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eSome contracts allow price pass-throughs, but typical lag of 30–90 days means inflation spikes cut gross margin—Aptar’s adjusted gross margin fell to 31.8% in 2022 from 34.2% in 2021.\u003c\/p\u003e\n\u003cp\u003eThis reliance on volatile global commodity markets keeps the cost base vulnerable; hedging covers only a portion and raw-material-driven input inflation remains a recurring margin risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining AptarGroup’s global lead in precision dispensing needs heavy capex; the company spent $145 million on capital expenditures in FY2024 (ended Dec 31, 2024), up 12% year-over-year, reflecting machinery and automation upgrades.\u003c\/p\u003e\n\u003cp\u003eUpgrading production lines to meet tighter EU REACH and energy-efficiency rules and new technical specs can compress free cash flow; Aptar’s 2024 free cash flow was $352 million, down 6% from 2023.\u003c\/p\u003e\n\u003cp\u003eManagement must balance these recurring investments with shareholder returns—Aptar paid $143 million in dividends and buybacks in 2024—creating a persistent tension between growth capex and capital returned to investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAptar still earns roughly 65% of 2024 revenue from North America and Western Europe, regions with annual GDP growth around 1–2% versus 4–6% in key developing markets, limiting upside. This geographic concentration gives stability but caps revenue expansion and margins compared with peers growing faster in Asia and Latin America. Over-reliance on these saturated markets risks slower EPS growth and market-share loss to more aggressive competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCyclicality in Beauty and Home Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Beauty and Home segment is tied to discretionary spending and saw revenue decline 7% YoY in Q3 2024 vs Pharma's flat performance, making sales volatile during downturns.\u003c\/p\u003e\n\u003cp\u003eEconomic shocks or rapid trend shifts can cut demand for luxury dispensers within weeks, causing quarterly EPS swings and harder forecasting for consolidated results.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~7% Q3 2024 Beauty\/Home revenue drop\u003c\/li\u003e\n\u003cli\u003ePharma revenue stable in same quarter\u003c\/li\u003e\n\u003cli\u003eHigher forecast variance in consolidated EPS\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of Global Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpaptar manages manufacturing sites across countries and navigating varying fda eu mdr china nmpa rules raises admin logistical burdens that increase sg corporate reported in coordinating global supply chains keeping uniform quality needs costly oversight erp investments spent on it decision cycles can hurt responsiveness rapid segments like pharma packaging. internal inefficiencies have contributed to a point margin drag versus peers recent quarters.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e46 sites, 18 countries\u003c\/li\u003e\n\u003cli\u003e~9.8% SG\u0026amp;A of sales (2024)\u003c\/li\u003e\n\u003cli\u003e~$75m IT\/capex spend (2024)\u003c\/li\u003e\n\u003cli\u003e1.5–2.0 pp margin drag vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/paptar\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAptar hit by resin cost shock, heavy capex and concentrated markets squeezing margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAptar faces raw-material cost swings (resin ~20–25% of COGS; spot +45% in 2021–22) that pressured adjusted gross margin to 31.8% in 2022, heavy capex ($145m in FY2024) and compliance costs that cut FCF to $352m in 2024, revenue concentration (65% North America\/Western Europe) limiting growth, plus operational complexity across 46 sites driving ~9.8% SG\u0026amp;A and a 1.5–2.0 pp margin drag versus peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResin % of COGS\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResin spot change\u003c\/td\u003e\n\u003ctd\u003e+~45% (2021–22)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. gross margin\u003c\/td\u003e\n\u003ctd\u003e31.8% (2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$145m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$352m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003e65% NA \u0026amp; WE (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites \/ countries\u003c\/td\u003e\n\u003ctd\u003e46 \/ 18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e~9.8% of sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin drag vs peers\u003c\/td\u003e\n\u003ctd\u003e1.5–2.0 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAptar SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Aptar SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality and fully editable for your use.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full report; buying unlocks the complete, detailed version with supporting insights and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752127312249,"sku":"aptar-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aptar-swot-analysis.png?v=1772238078","url":"https:\/\/matrixbcg.com\/products\/aptar-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}